Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...

Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth ...

Uganda is registering around 38,000 new infections despite the deployment of different interventions such as condoms and oral ...